Mining for humoral correlates of HIV control and latent reservoir size.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
10 2020
Historique:
received: 24 10 2019
accepted: 06 08 2020
entrez: 13 10 2020
pubmed: 14 10 2020
medline: 1 1 2021
Statut: epublish

Résumé

While antiretroviral therapy (ART) has effectively revolutionized HIV care, the virus is never fully eliminated. Instead, immune dysfunction, driven by persistent non-specific immune activation, ensues and progressively leads to premature immunologic aging. Current biomarkers monitoring immunologic changes encompass generic inflammatory biomarkers, that may also change with other infections or disease states, precluding the antigen-specific monitoring of HIV-infection associated changes in disease. Given our growing appreciation of the significant changes in qualitative and quantitative properties of disease-specific antibodies in HIV infection, we used a systems approach to explore humoral profiles associated with HIV control. We found that HIV-specific antibody profiles diverge by spontaneous control of HIV, treatment status, viral load and reservoir size. Specifically, HIV-specific antibody profiles representative of changes in viral load were largely quantitative, reflected by differential HIV-specific antibody levels and Fc-receptor binding. Conversely, HIV-specific antibody features that tracked with reservoir size exhibited a combination of quantitative and qualitative changes marked by more distinct subclass selection profiles and unique HIV-specific Fc-glycans. Our analyses suggest that HIV-specific antibody Fc-profiles provide antigen-specific resolution on both cell free and cell-associated viral loads, pointing to potentially novel biomarkers to monitor reservoir activity.

Identifiants

pubmed: 33048992
doi: 10.1371/journal.ppat.1008868
pii: PPATHOGENS-D-19-01937
pmc: PMC7553335
doi:

Substances chimiques

Anti-Retroviral Agents 0
Biomarkers 0
HIV Antibodies 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008868

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131975
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI080289
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126603
Pays : United States

Déclaration de conflit d'intérêts

The authors affiliated with Gilead Sciences Inc are current employees of the company and may own company stock. This does not alter our adherence to all PLOS Pathogens policies on sharing data and materials.

Références

Science. 2015 Jun 5;348(6239):aaa0698
pubmed: 26045439
AIDS. 2009 May 15;23(8):897-906
pubmed: 19414990
Nat Rev Immunol. 2009 Apr;9(4):235-45
pubmed: 19319142
J Immunol Methods. 2011 Mar 7;366(1-2):8-19
pubmed: 21192942
PLoS Pathog. 2016 Jun 02;12(6):e1005677
pubmed: 27253379
PLoS One. 2012;7(10):e46143
pubmed: 23056251
Elife. 2014 Sep 12;3:e03821
pubmed: 25217531
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
J Exp Med. 1998 Jul 20;188(2):233-45
pubmed: 9670036
J Clin Med Res. 2010 Mar 20;2(2):55-61
pubmed: 21811520
Curr HIV/AIDS Rep. 2017 Apr;14(2):72-81
pubmed: 28401492
J Immunol Methods. 2006 Jan 20;308(1-2):53-67
pubmed: 16343526
Nat Med. 2018 Oct;24(10):1590-1598
pubmed: 30177821
N Engl J Med. 1983 Aug 25;309(8):453-8
pubmed: 6224088
Blood. 2004 Aug 15;104(4):942-7
pubmed: 15117761
J Infect Dis. 2016 Aug 1;214(3):390-8
pubmed: 27122593
J Infect Dis. 2018 Jan 30;217(4):521-528
pubmed: 29165684
AIDS. 2018 Feb 20;32(4):443-450
pubmed: 29239894
J Immunol Methods. 2017 Apr;443:33-44
pubmed: 28163018
Nat Med. 2007 Jan;13(1):46-53
pubmed: 17173051
AIDS. 2005 Mar 4;19(4):381-9
pubmed: 15750391
Immunol Rev. 2017 Jan;275(1):33-48
pubmed: 28133792
Elife. 2014 Oct 16;3:e04742
pubmed: 25321627
J Acquir Immune Defic Syndr. 2011 May 1;57(1):9-15
pubmed: 21283016
PLoS Pathog. 2016 Apr 27;12(4):e1005535
pubmed: 27119536
Immunol Rev. 2013 Jul;254(1):207-24
pubmed: 23772622
Trends Immunol. 2017 May;38(5):358-372
pubmed: 28385520
Blood Adv. 2017 Nov 17;1(25):2329-2342
pubmed: 29296883
Sci Transl Med. 2014 Mar 19;6(228):228ra39
pubmed: 24648342
Mol Syst Biol. 2018 Mar 26;14(3):e7881
pubmed: 29581149
Curr Opin HIV AIDS. 2010 Nov;5(6):498-503
pubmed: 20978393
Immunology. 2013 Feb;138(2):116-23
pubmed: 23173935
J Immunol Methods. 2015 Feb;417:34-44
pubmed: 25523925
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018-23
pubmed: 9294155
PLoS Pathog. 2016 Jan 08;12(1):e1005315
pubmed: 26745376
J Immunol Methods. 2015 Oct;425:27-36
pubmed: 26078040
J Immunol Methods. 2018 Apr;455:24-33
pubmed: 29395167
J Clin Invest. 2013 May;123(5):2183-92
pubmed: 23563315
J Virol. 2007 Mar;81(5):2440-8
pubmed: 17182686
J Virol. 2009 Aug;83(15):7641-8
pubmed: 19458000
Trends Microbiol. 2015 Apr;23(4):192-203
pubmed: 25747663
AIDS. 1999 May 28;13(8):F59-62
pubmed: 10371167
Cell. 2016 Aug 11;166(4):1004-1015
pubmed: 27453467
PLoS Pathog. 2018 Apr 9;14(4):e1006987
pubmed: 29630668
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161
pubmed: 22474613
J Gerontol A Biol Sci Med Sci. 2014 Jul;69(7):779-89
pubmed: 24325898
Cell. 2015 Nov 5;163(4):988-98
pubmed: 26544943
J Virol. 2010 Feb;84(3):1631-6
pubmed: 19923174
Sci Transl Med. 2014 Mar 19;6(228):228ra38
pubmed: 24648341
Nat Rev Rheumatol. 2017 Oct;13(10):621-630
pubmed: 28905852

Auteurs

Jishnu Das (J)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.
Department of Biological Engineering, MIT, Cambridge, United States of America.

Anush Devadhasan (A)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Caitlyn Linde (C)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Tom Broge (T)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Jessica Sassic (J)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Max Mangano (M)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Sean O'Keefe (S)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Todd Suscovich (T)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Hendrik Streeck (H)

Institute for HIV Research, Essen, Germany.

Alivelu Irrinki (A)

Gilead Life Sciences, San Francisco, CA, United States of America.

Chris Pohlmeyer (C)

Gilead Life Sciences, San Francisco, CA, United States of America.

Gundula Min-Oo (G)

Gilead Life Sciences, San Francisco, CA, United States of America.

Shu Lin (S)

Thayer School of Engineering, Dartmouth College, Hanover, United States of America.

Joshua A Weiner (JA)

Thayer School of Engineering, Dartmouth College, Hanover, United States of America.

Thomas Cihlar (T)

Gilead Life Sciences, San Francisco, CA, United States of America.

Margaret E Ackerman (ME)

Thayer School of Engineering, Dartmouth College, Hanover, United States of America.

Boris Julg (B)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Steven Deeks (S)

Department of Medicine, University of California San Francisco, San Francisco, United States of America.

Douglas A Lauffenburger (DA)

Department of Biological Engineering, MIT, Cambridge, United States of America.

Galit Alter (G)

Ragon Institute of MGH, MIT and Harvard, Cambridge, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH